Guizhou Bailing Group Pharmaceutical Co., Ltd. (SHE:002424)
China · Delayed Price · Currency is CNY 4.670
-0.050 (-1.06%)
Sep 10, 2026, 12:14 PM CST
SHE:002424 Revenue
Guizhou Bailing Group Pharmaceutical had revenue of 326.36M CNY in the quarter ending June 30, 2026, a decrease of -53.47%. This brings the company's revenue in the last twelve months to 2.56B, down -18.68% year-over-year. In the year 2025, Guizhou Bailing Group Pharmaceutical had annual revenue of 3.05B, down -20.31%.
Revenue (ttm)
2.56B
Revenue Growth
-18.68%
P/S Ratio
2.52
Revenue / Employee
447.44K
Employees
5,715
Market Cap
6.44B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | -776.76M | -20.31% |
| Dec 31, 2024 | 3.83B | -437.59M | -10.26% |
| Dec 31, 2023 | 4.26B | 722.84M | 20.42% |
| Jan 1, 2023 | 3.54B | 429.01M | 13.79% |
| Jan 1, 2022 | 3.11B | 23.24M | 0.75% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Northeast Pharmaceutical Group | 6.56B |
| KPC Pharmaceuticals,Inc. | 4.87B |
| ZhuZhou QianJin Pharmaceutical Co.,Ltd | 3.73B |
| Cisen Pharmaceutical | 3.40B |
| Shandong Wit Dyne Health | 1.91B |
| Hunan Warrant Pharmaceutical Co.,Ltd | 1.45B |
| Hunan Er-Kang Pharmaceutical | 1.05B |
| Hainan Haiyao | 702.17M |